Zinbryta vs. Gilenya

• Are Gilenya and Zinbryta the Same Thing?
• What Are Possible Side Effects of Zinbryta?
• What Are Possible Side Effects of Gilenya?
• What Is Zinbryta?
• What Is Gilenya?
• What Drugs Interact with Zinbryta?
• What Drugs Interact with Gilenya?
• How Should Zinbryta Be Taken?
• How Should Gilenya Be Taken?

Zinbryta (daclizumab) and Gilenya (fingolimod) are used to treat patients with relapsing forms of multiple sclerosis (MS).

Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Zinbryta and Gilenya belong to different drug classes. Zinbryta is an interleukin-2 receptor blocking antibody and Gilenya is a sphingosine 1-phosphate receptor modulator.

Side effects of Zinbryta and Gilenya that are similar include influenza and increased liver transaminases.

Side effects of Zinbryta that are different from Gilenya include runny or stuffy nose, upper respiratory tract infection, bronchitis, skin rash (including drug rash), mouth pain, sore throat, eczema, swollen lymph nodes, depression, anemia, acne, and fever.

Side effects of Gilenya that are different from Zinbryta include headache, tired feeling, stuffy nose, sinus pain, diarrhea, back pain, and cough.

Zinbryta may interact with drugs or herbal products that are toxic to the liver.

Gilenya may interact with beta-blockers, calcium channel blockers, citalopram, chlorpromazine, digoxin, erythromycin, haloperidol, ketoconazole, medications to control the immune system, medications for cancer, heart or blood pressure medicines, and methadone.

Common side effects of Zinbryta include:

• runny or stuffy nose
• upper respiratory tract infection
• rash, including drug rash
• influenza
• skin rash
• mouth pain
• sore throat
• bronchitis
• eczema
• swollen lymph nodes
• depression
• increased alanine aminotransferase (ALT)
• acne
• anemia, and
• fever

Less common side effects of Zinbryta include:

• abnormal liver function test,
• decreased lymphocyte count
• diarrhea
• dry skin
• skin redness
• hair bumps (folliculitis)
• increased liver enzymes
• laryngitis
• enlarged lymph nodes
• pneumonia
• itching
• psoriasis
• skin peeling
• toxic skin eruption, and
• viral infection

Common side effects of Gilenya include:

• headache,
• tired feeling,
• influenza,
• stuffy nose,
• sinus pain,
• diarrhea,
• back pain,
• liver transaminase elevations, and
• cough.

Gilenya can affect your immune system's ability to fight an infection while you are taking the medication and for 2 months after your last dose. Tell your doctor right away if you develop signs of an infection such as:

• persistent cough or sore throat,
• difficulty breathing,
• fever,
• chills, or
• cold/flu symptoms.

Zinbryta (daclizumab) injection is an interleukin-2 receptor blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator used to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of exacerbations and to delay physical disability.

Zinbryta may interact with hepatotoxic drugs or herbal products. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before taking Zinbryta. It is unknown if it would affect a fetus. It is unknown if Zinbryta passes into breast milk or if it would affect a nursing infant. Consult your doctor before breastfeeding.

Gilenya may interact with beta-blockers, calcium channel blockers, citalopram, chlorpromazine, digoxin, erythromycin, haloperidol, ketoconazole, medications to control the immune system, medications for cancer, heart problems, or high blood pressure, and methadone. Tell your doctor all medications and supplements you use. Gilenya may cause fetal harm. It takes approximately 2 months for Gilenya to be eliminated from the body. Women should avoid pregnancy during treatment with Gilenya and for 2 months after treatment. It is not known if Gilenya passes into breast milk. Women and their doctors should decide whether to take Gilenya or breastfeed. Women should not do both.

The recommended dosage of Zinbryta is 150 milligrams once monthly.

The recommended dose for Gilenya is 0.5 mg orally once daily, with or without food.